{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:35:04Z","timestamp":1770986104425,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"am","delay-in-days":390,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.therap.2022.02.001","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:18:21Z","timestamp":1643973501000},"page":"585-590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacologie du cannabidiol\u00a0: points de vigilance, cons\u00e9quences et risques chez l\u2019homme"],"prefix":"10.1016","volume":"77","author":[{"given":"Jo\u00eblle","family":"Micallef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Batisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Revol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2022.02.001_bib0175","series-title":"EPIDYOLEX (cannabidiol) Avis sur les m\u00e9dicaments","author":"Haute autorit\u00e9 de sant\u00e9","year":"2020"},{"key":"10.1016\/j.therap.2022.02.001_bib0180","series-title":"Bulletin d\u2019addictovigilance. Que (devrait-on) savoir sur la pharmacologie du cannabidiol","author":"R\u00e9seau fran\u00e7ais d\u2019addictovigilance","year":"2020"},{"key":"10.1016\/j.therap.2022.02.001_bib0185","doi-asserted-by":"crossref","first-page":"e00682","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD","volume":"8","author":"de Almeida","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.therap.2022.02.001_bib0190","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.euroneuro.2013.10.012","article-title":"Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience","volume":"24","author":"Foga\u00e7a","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.therap.2022.02.001_bib0195","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41401-018-0071-1","article-title":"Computational systems pharmacology analysis of cannabidiol: a combination of chemogenomics-knowledgebase network analysis and integrated in silico modeling and simulation","volume":"40","author":"Bian","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.therap.2022.02.001_bib0200","doi-asserted-by":"crossref","first-page":"114004","DOI":"10.1016\/j.bcp.2020.114004","article-title":"Altered dopamine D3\u00a0receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment","volume":"177","author":"Stark","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.therap.2022.02.001_bib0205","doi-asserted-by":"crossref","first-page":"e920","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.therap.2022.02.001_bib0210","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.therap.2022.02.001_bib0215","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.therap.2022.02.001_bib0220","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.therap.2022.02.001_bib0225","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.seizure.2020.09.010","article-title":"Interaction of cannabidiol with other antiseizure medications: A narrative review","volume":"86","author":"Gilmartin","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.therap.2022.02.001_bib0230","series-title":"Open Medic. Base compl\u00e8te sur les d\u00e9penses de m\u00e9dicaments interr\u00e9gimes","year":"2021"},{"key":"10.1016\/j.therap.2022.02.001_bib0235","series-title":"Base de donn\u00e9es publique des m\u00e9dicaments. RCP de la coumadine","year":"2021"},{"key":"10.1016\/j.therap.2022.02.001_bib0240","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ebcr.2017.10.001","article-title":"An interaction between warfarin and cannabidiol, a case report","volume":"9","author":"Grayson","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.therap.2022.02.001_bib0245","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/jcph.1557","article-title":"A Review of cannabis and interactions with anticoagulant and antiplatelet agents","volume":"60","author":"Greger","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.02.001_bib0250","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/ajhp\/zxaa268","article-title":"Warfarin dose adjustment required after cannabidiol initiation and titration","volume":"77","author":"Cortopassi","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.therap.2022.02.001_bib0255","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/ajt.15398","article-title":"Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus","volume":"19","author":"Leino","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.therap.2022.02.001_bib0260","doi-asserted-by":"crossref","first-page":"e20193256","DOI":"10.1542\/peds.2019-3256","article-title":"Clinically significant drug-drug interaction between methadone and cannabidiol","volume":"145","author":"Madden","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.therap.2022.02.001_bib0265","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1124\/jpet.105.098541","article-title":"Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana","volume":"317","author":"Zhu","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.therap.2022.02.001_bib0270","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.lfs.2011.01.013","article-title":"Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats","volume":"88","author":"Murillo-Rodr\u00edguez","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.therap.2022.02.001_bib0275","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","article-title":"Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial","volume":"88","author":"Schoedel","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.therap.2022.02.001_bib0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers","volume":"172","author":"Babalonis","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2022.02.001_bib0285","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fpsyt.2019.00063","article-title":"The endocannabinoid system and cannabidiol's promise for the treatment of substance use disorder","volume":"10","author":"Chye","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2022.02.001_bib0290","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drugalcdep.2007.11.017","article-title":"Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol","volume":"94","author":"Vann","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2022.02.001_bib0295","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.drugalcdep.2016.05.016","article-title":"Enhanced discriminative stimulus effects of \u0394(9)-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys","volume":"165","author":"McMahon","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2022.02.001_bib0300","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.forsciint.2018.08.009","article-title":"Cannabinoid concentrations in blood and urine after smoking cannabidiol joints","volume":"291","author":"Meier","year":"2018","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.therap.2022.02.001_bib0305","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00414-018-01994-y","article-title":"Cannabinoid concentrations in confiscated cannabis samples and in whole blood and urine after smoking CBD-rich cannabis as a \u201ctobacco substitute\u201d","volume":"133","author":"H\u00e4dener","year":"2019","journal-title":"Int J Legal Med"},{"key":"10.1016\/j.therap.2022.02.001_bib0310","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.3390\/ijerph182111158","article-title":"Routes of administration of illicit drugs among young Swiss men: their prevalence and associated socio-demographic characteristics and adverse outcomes","volume":"18","author":"Est\u00e9vez-Lamorte","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.therap.2022.02.001_bib0315","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.forsciint.2018.10.019","article-title":"The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids","volume":"294","author":"Poklis","year":"2019","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.therap.2022.02.001_bib0320","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/15563650.2019.1619758","article-title":"Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient","volume":"58","author":"Rianprakaisang","year":"2020","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.therap.2022.02.001_bib0325","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1038\/s41598-021-88389-z","article-title":"CBD, a precursor of THC in e-cigarettes","volume":"11","author":"Cz\u00e9g\u00e9ny","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.therap.2022.02.001_bib0330","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.euroneuro.2017.10.037","article-title":"Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC","volume":"27","author":"Hlo\u017eek","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.therap.2022.02.001_bib0335","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s00213-019-05246-8","article-title":"Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition","volume":"236","author":"Arkell","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"10.1016\/j.therap.2022.02.001_bib0170","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/jat\/bkaa008","article-title":"Vaping pure cannabidiol e-cigarettes does not produce detectable amount of \u03949-THC in human blood","volume":"44","author":"Kintz","year":"2021","journal-title":"J Anal Toxicol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722000312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722000312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:56Z","timestamp":1758567296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595722000312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0040595722000312"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2022.02.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologie du cannabidiol\u00a0: points de vigilance, cons\u00e9quences et risques chez l\u2019homme","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2022.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}